Currently Viewing:
The International Society for Pharmacoeconomics and Outcomes Research
Value Assessment Frameworks Should Represent a Spectrum of Patient Preferences
September 08, 2017
Dr Patricia Danzon: Learning From European Health Systems
August 30, 2017
Dr Ilene Hollin: One-Size-Fits-All to Value Doesn't Work
August 23, 2017
Dr Patricia Danzon Highlights European Examples of Restraining Drug Prices
August 16, 2017
Dr Ilene Hollin Outlines Differing Definitions of Value
August 09, 2017
Dr Patricia Danzon: Cost Effective Doesn't Mean Affordable
August 03, 2017
Dr Michael Sherman on Performance-Based Risk-Sharing Agreements
July 28, 2017
Dr David Cutler Assesses the Political Odds of Drug Pricing Reform
July 25, 2017
Dr Steve Pearson on Using Health Technology Assessment to Guide Decision Making
July 23, 2017
Dr Gail Wilensky: Increased Competition a Better Drug Pricing Solution Than Cost Controls
July 16, 2017
Dr Steve Pearson on Data Needed to Evaluate Clinical and Economic Effects of New Therapies
July 14, 2017
Currently Reading
Dr David Cutler: Trump Administration's Attention Not on Value-Based Purchasing
July 09, 2017
Dr Steve Pearson: Patient Perspectives Guide ICER Value Framework Development
July 04, 2017
Dr Scott Ramsey Addresses the Need for Differential Pricing Structures for Drugs
July 02, 2017
Dr Gail Wilensky Raises Questions About Medicaid's Matching Grant Structure
June 25, 2017
Dr Steve Pearson Explains How ICER Price Benchmarks Align Cost With Patient Benefits
June 22, 2017
Dr David Cutler Discusses Opportunities for Bipartisan ACA Reform
June 20, 2017
Dr Scott Ramsey on Challenges of Determining Cost Effectiveness of Novel Cancer Treatments
June 19, 2017
Dr Steve Pearson's Outlook on the Ongoing Updates to ICER's Value Framework
June 18, 2017

Dr David Cutler: Trump Administration's Attention Not on Value-Based Purchasing

The Trump administrationís healthcare priorities have mainly focused on replacing the Affordable Care Act or reforming Medicaid, leading to concerns that value-based purchasing efforts will be left in the dust, said David M. Cutler, PhD, of Harvard University.


The Trump administration’s healthcare priorities have mainly focused on replacing the Affordable Care Act (ACA) or reforming Medicaid, leading to concerns that value-based purchasing efforts will be left in the dust, said David M. Cutler, PhD, of Harvard University.

Transcript (slightly modified)

Do you think this country’s trajectory of moving to value-based care will be altered under the current administration?

The move towards value-based care is, of course, an extremely important one. I have not heard the Trump administration say what its philosophy is about this. I am worried on 2 counts. One is, many of the programs that the Obama administration had started are either being slowed down or being cancelled entirely, which I don’t think is good news. But second, I also think their attention is elsewhere, so their attention is on repealing the ACA, or what should be in a replacement bill, or on Medicaid and work requirements.

Their attention isn’t on value-based purchasing. That suggests to me that they’re not going to be actively thinking about it, and this is one of those topics that you kind of have to put the effort into doing, because it doesn’t happen on its own.

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!